A new therapy that first made headlines in 2021 is now showing potential to heal human cartilage. Developed by scientists at Northwestern University, the technique was initially created to repair ...

In its two lead cancer assets, STP705 and STP707, Sirnaomics is using the technology to deliver two siRNA oligonucleotides to knock down TGF-β1 and COX-2 gene expression. TGF-β1 and COX-2 are ...

More information: Frederik Link et al, ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-β1 activation, Gut (2024). DOI: 10.1136/gutjnl-2024-333213 Isabel Fabregat et ...

Both STP705 and STP707 are made of two siRNA oligonucleotides that hit transforming growth factor beta 1 (TGF-β1) and cyclooxygenase 2 (COX-2) mRNA, gatekeeper targets for oncology and fibrosis.

It has been demonstrated in animal studies that antifibrotic agents that inactivate transforming growth factor (TGF)-β1 have been effective at decreasing scar tissue formation. Several studies have ...